New Virus-Immunotherapy combo tackles Hard-to-Treat cancers

NCT ID NCT07154108

Not yet recruiting Disease control Sponsor: Sichuan University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial is testing a new approach for people with recurrent or metastatic head/neck cancer or esophageal cancer. The treatment combines a virus that delivers endostatin directly into tumors with an immunotherapy drug (PD-1 inhibitor). The goal is to see if the combination is safe and can shrink tumors. About 40 participants will be enrolled across two groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: recombinant human endostatin adenovirus (a virus that delivers endostatin to tumors) plus a PD-1 inhibitor (immunotherapy)
What this could lead to: If this works, it could point toward a new combination treatment for advanced head/neck and esophageal cancers that have stopped responding to standard therapy.
What could go wrong: This is a very early Phase 1 trial with only 40 people, so it is primarily testing safety. The combination may not shrink tumors or may cause serious side effects. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms esophageal squamous cell carcinoma head and neck cancer Head and Neck Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL CANCER HEAD AND NECK CANCER (H&AMP;AMP;AMP;N)

Contacts and locations

Locations

West China Hospital of Sichuan University

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.